The purpose of this research is to learn whether the investigational study drug BMS-986504 works to treat metastatic (cancer that has spread in the body) pancreatic ductal adenocarcinoma (PDAC) when combined with standard chemotherapy in participants with homozygous MTAP deletion or MTAP loss, who have not previously received treatment for metastatic PDAC.
Thank you for your interest, but this study is not currently enrolling.
North Carolina (Statewide)
Ashwin Somasundaram
Medicine- Oncology
Clinical or Medical
Interventional
Cancer (Colorectal)
25-2143
Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.
Questions?
